insitro, the AI-driven therapeutics company, has announced the acquisition of CombinAbleAI, a pioneering Israeli biotech firm specializing in AI-powered biologic drug design, and the launch of its new TherML™ (Therapeutic Machine Learning) platform. The acquisition, expected to close in late January 2026, marks a major milestone in insitro’s mission to build a fully integrated, modality-agnostic drug discovery engine. TherML unifies the design of small molecules, oligonucleotides, antibodies, and other complex biologics within a single AI platform, enabling end-to-end therapeutic development guided by causal biology. Philip Tagari, insitro’s Chief Scientific Officer, emphasized that traditional drug discovery often prioritizes potency first and assesses developability later—leading to costly late-stage failures. TherML changes this paradigm by treating potency, stability, manufacturability, and safety as interdependent design criteria from the outset. By integrating CombinAbleAI’s physics-informed AI models with insitro’s causal biology platform, the company can simultaneously optimize for efficacy and developability, drastically reducing the risk of attrition in clinical development. CombinAbleAI’s technology leverages AI and molecular dynamics simulations trained on over 100,000 surrogate models to predict protein structure and flexibility with high accuracy—critical for designing complex biologics like multi-specific antibodies and T-cell engagers. This capability fills a key gap in insitro’s existing toolkit, which already includes proprietary Quantitative Adaptive Libraries for small molecule optimization and AI-driven automation for siRNA design in oligonucleotides. TherML also incorporates advanced machine learning models for predicting ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, drawing on insitro’s internal data and industry partnerships. The platform is directly integrated with insitro’s automated laboratories, allowing rapid experimental validation and continuous feedback to improve AI predictions. This closed-loop system accelerates the path from target identification to clinic-ready candidates, making drug discovery more predictable, scalable, and efficient. Daphne Koller, Ph.D., founder and CEO of insitro, highlighted the strategic importance of the acquisition, calling the CombinAbleAI team “fellow insitrocytes” and noting that their addition strengthens insitro’s global R&D footprint. The new team will operate from a dedicated R&D center in Israel, complementing insitro’s existing sites in the U.S., Poland, and Malaysia. Noam Katz, co-founder of CombinAbleAI, expressed excitement about joining insitro, stating that the integration will enable reliable, rapid translation of high-value biological targets into functional therapeutics. CombinAbleAI was founded in 2023 within AION Labs, a unique venture studio backed by global pharmaceutical leaders including Merck KGaA, AstraZeneca, Pfizer, Teva, and Amazon Web Services, along with the Israel Biotech Fund, Amiti Ventures, and the Israel Innovation Authority. AION Labs’ mission is to build AI-native biotech companies that accelerate drug discovery through collaboration and innovation. insitro, which has raised approximately $800 million in capital—including $150 million from non-dilutive pharma partnerships—focuses on metabolic diseases and neuroscience. Its platform combines multimodal human and cellular data with machine learning to uncover the root causes of disease and design targeted therapies. With the launch of TherML, insitro is positioning itself as a leader in industrialized, AI-driven drug discovery, capable of delivering high-quality, developable candidates across all major therapeutic modalities.